EMERYVILLE, Calif. - NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare and wound care products, has launched a new marketing initiative to boost online sales of its Avenova brand. The campaign, which started earlier this week, incorporates text messaging and enhanced email strategies to engage customers and promote customer loyalty.
The company's CEO, Justin Hall, stated that the integration of text messaging aims to leverage the success of previous marketing efforts on social media and email, which have significantly increased customer engagement and sales. The SMS service is designed to provide immediate updates, exclusive discounts, and valuable content related to eye health to both existing and potential customers.
NovaBay reports that Avenova sales through social media channels in the first quarter of this year surged by over 160% compared to the same period last year. Additionally, revenues from the email marketing program have seen a consistent rise since mid-2023, with a growth of more than 360%. The company recently revamped its email marketing with fresh creative content and automation to maintain current customer interest and attract new prospects.
Avenova Antimicrobial Lid & Lash Solution, NovaBay's flagship product, is recommended by eye care professionals for conditions like blepharitis and dry-eye disease. It is available to consumers online, including through Amazon.com (NASDAQ:AMZN), and is noted for its effectiveness against a broad range of bacteria without causing irritation, making it safe for regular use.
NovaBay's portfolio also includes products such as the Avenova Eye Health Support supplement, Avenova Lubricating Eye Drops, Avenova Warm Eye Compress, and the i-Chek by Avenova for eyelid health monitoring. The company provides the Avenova Allograft, a prescription-only amniotic tissue product, through eye care professionals in the U.S.
The company's forward-looking statements suggest an optimistic outlook on the marketing strategy's impact on sales and customer engagement. However, these statements are subject to various risks and uncertainties that could cause actual results to differ materially.
This report is based on a press release statement from NovaBay Pharmaceuticals, Inc. and presents the company's marketing plans and product offerings without promotion or endorsement.
InvestingPro Insights
In light of NovaBay Pharmaceuticals' efforts to ramp up its marketing initiatives, a closer look at the company’s financial health through InvestingPro data may be of interest to investors. As of the last twelve months ending Q4 2023, NovaBay reported revenue of $14.73 million, reflecting a modest year-over-year growth of 2.24%.
Despite this growth, the company has faced challenges, as indicated by an operating income margin of -33.97%, suggesting that expenses significantly outweighed gross profits, which stood at $7.89 million.
Stock performance metrics from InvestingPro also paint a picture of recent volatility and decline. Over the past month, the company's stock price has decreased by 39.5%, and over the last six months, it has taken a significant hit with a 76.46% drop.
This trend aligns with an InvestingPro Tip that highlights the stock's volatility and the fact that it has fared poorly in recent times. Moreover, analysts do not expect NovaBay to be profitable this year, as per another InvestingPro Tip, which may be a concern for potential investors.
For those considering an investment in NovaBay, the InvestingPro platform offers additional insights, with a total of 14 InvestingPro Tips that can provide a deeper understanding of the company's financial position and stock performance. To explore these insights further, and to make more informed investment decisions, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.